World News

The arrangement gives Ona Therapeutics access to WuXi XDC’s capabilities across ADC development and manufacturing as it advances the candidate towards clinical development.

The ACUVUE OASYS MAX 2 Week lens is part of the wider ACUVUE OASYS MAX portfolio, which J&J developed to provide advanced options for people who use reusable contact lenses.

Novadip will use the proceeds to advance NVD003, its lead autologous cell-based therapy, through late-stage clinical development and regulatory preparation.

Patients have an average lifespan of about 15 years, while an estimated 3,000 to 5,000 people in commercially accessible markets live with the condition.

The five-day meeting in Geneva focused on developing the Pathogen Access and Benefit-Sharing (PABS) annex to the WHO Pandemic Agreement, with governments working towards a system that is practical, equitable and feasible to implement.

Launched at the World Health Assembly in 2025, Aira addresses three challenges facing primary healthcare: staff shortages, inconsistent use of clinical guidelines and the administrative workload that limits the time health workers spend with patients.

The proposed expansion would allow its use in adolescents aged 12 to 17 years with moderate to severe chronic hand eczema (CHE) when topical corticosteroids are inadequate or inappropriate.

Under the agreement, 1ST Biotherapeutics will receive US$1.8 million upfront and an additional US$1.8 million payment in the near term.

The projects form part of Reckitt’s broader effort to increase production and bring research activities closer to its U.S. commercial operations.

Roche will take responsibility for subsequent development activities, including preclinical research, and oversee the programmes as they progress towards potential commercialisation.